ABBV
APGE
The deal just got a lawyer-shaped speed bump
AbbVie’s proposed buyout of Apogee Therapeutics is drawing heat from Kahn Swick & Foti, which says it’s investigating whether the $135.11-per-share cash offer was fair and whether the process behind it was buttoned up properly. Translation: the deal is real, but so is the classic merger question, “Wait, did management leave money on the table?”
Why this matters for ABBV
For AbbVie, this isn’t just another shopping trip. A big acquisition can be a pipeline booster, but it also comes with integration risk, financing considerations, and the not-so-fun possibility of overpaying for future growth. If the market starts thinking the price is rich, that can put a little stink on an otherwise strategic move.
The usual merger drama, now with extra paperwork
Shareholder investigations like this often become the corporate version of checking the receipt at the bottom of the grocery bag. Sometimes they fade into background noise. Sometimes they pile pressure on the board, delay closing, or squeeze in extra disclosures.
- Deal value: about $10.9 billion
- Offer price: $135.11 in cash per Apogee share
- Main question: was the price/process good enough for shareholders?
Big picture: AbbVie is still trying to buy growth the old-fashioned way — with a giant check. But in M&A, the price tag is never the end of the story; it’s usually the opening scene.